Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second Psilocybin Retreat for Anxiety in Metastatic Cancer
NCT06644170Phase 1Completed
- Sponsor
- University of Washington
- Start
- Nov 2024
- Primary completion
- Sep 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in anxiety disorder and major depressive disorder (MDD), sponsored by University of Washington. Primary endpoint: Incidence of adverse events (AEs) at 24 weeks. Started Nov 2024; status: completed.
02
Drugs
psilocybin
03
Conditions
anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06644170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06644170.